Breaking News

Ambrilia, ZBx Enter Licensing Deal

Ambrilia has entered into an agreement granting ZBx Corp. an option to acquire exclusive worldwide rights to Ambrilia's PSP-94 reagents and related intellectual property.

Ambrilia has entered into an agreement granting ZBx Corp. an option to acquire exclusive worldwide rights to Ambrilia’s PSP-94 reagents and related intellectual property. If ZBx exercises its option, Ambrilia would be eligible to receive as much as $50,000 upfront, sales milestones, royalties on sales, as well as a percentage of proceeds from any sublicenses or sale of PSP-94. ZBx will cover further development, manufacturing and commercialization costs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters